NOTE 6. INCOME TAXES

 

The income tax expense consists of the following for the years ended December 31:

 

   2025   2024 
Current          
Federal  $43   $(287)
State   26    22 
Foreign   752    633 
Deferred          
Federal   (581)   127 
State   (117)   (119)
Foreign   140    (20)
Income tax expense  $263   $356 

 

The statutory rate reconciliation is as follows for the years ended December 31:

 

   2025   2024 
Statutory rate  $2   $(200)
State income tax   (97)   (101)
Effect of foreign operations   88   (63)

Maquiladora tax

   

128

    

187

 
Cross-border tax laws   147    492 
Research and development   (73)   13 
Nontaxble and nondeductable items   28    (21

)

US permanent differences   14    (46)
Other   26    95 
Income tax expense (benefit)  $263   $356 

 

On July 4, 2025, H.R. 1, the One Big Beautiful Bill Act (the “OBBB Act”), was enacted in the United States. The OBBB Act introduced several tax law changes relevant to the manufacturing industry. Key provisions include the restoration of 100% bonus depreciation for qualified property, expanded interest deductibility under Internal Revenue Code Section 163(j) and other international tax reforms affecting global supply chains and cross-border operations. The OBBB Act also reinstates immediate expensing for domestic research and development expenditures for tax years beginning after December 31, 2024, reversing prior rules that required capitalization and amortization of such costs. Due to the impact on GILTI provisions, the Company does not intend to take 100% bonus depreciation. It also does not intend to immediately expense R&D expenditures for 2025 or accelerate the deduction of previously capitalized R&D expenditures.

 

Income and loss from operations before income taxes was derived from the following jurisdictions for the years ended December 31:

 

   2025   2024 
United States  $(3,210)  $(3,284)
Foreign   3,221    2,345 
Total  $11   $(939)

 

 

Deferred tax assets (liabilities) consist of the following as of December 31:

 

   2025   2024 
Deferred tax assets          
Inventory  $585   $535 
Net operating losses   140    241 
Stock-based compensation   337    277 
Other accruals   45    94 
Lease accounting lease liability   1,484    1,624 
Capitalized research expenses   1,078    928 
Tax credit carryforwards   210    151 
Intangibles   351    422 
Other   1,145    542 
Total deferred tax assets   5,375    4,814 
           
Deferred tax liabilities          
Lease accounting lease asset   (1,399)   (1,562)
Withholding tax   (360)   (219)
Prepaid expenses   (171)   (186)
Property and equipment   (353)   (278)
Other   (58)   (213)
Total deferred tax liabilities   (2,341)   (2,458)
Net deferred tax assets  $3,034   $2,356 

 

The Company regularly assesses the need for a valuation allowance related to our deferred income tax assets to determine, based on the weight of the available positive and negative evidence, whether it is more likely than not that some or all of such deferred assets will not be realized. In our assessments, the Company considers recent financial operating results, potential sources of taxable income, the reversal of existing taxable differences, taxable income in prior carryback years, if permitted under tax law, and tax planning strategies. Based on our most recent assessment, for the year ended December 31, 2025, we have concluded that our deferred income tax assets are more likely than not to be realized. Our consolidated balance sheets as of December 31, 2025 and 2024 have a deferred tax asset of $3,394 and $2,575, respectively, related to our US taxable operations and a $360 and $219, respectively, deferred tax liability included other long-term liabilities related to our Chinese taxes, for a net deferred tax asset of $3,034 and $2,356, respectively.

 

As of December 31, 2025, we have no US Federal net operating loss carryforward and a Minnesota net operating loss carryforward (pre-tax, post-apportionment) of approximately $2,100.

 

As of December 31, 2025, the Company has US Federal and Minnesota R&D tax credits of approximately $100 and $100, respectively. These balances are recorded net of any uncertain tax position. The R&D credits have a 20-year carryforward for Federal purposes (begin to expire in 2044) and 15-year carryforward for Minnesota purposes (begin to expire in 2029).

 

 

The tax effects from uncertain tax positions can be recognized in our consolidated financial statements, only if the position is more likely than not to be sustained on audit, based on the technical merits of the position. We recognize the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The following tables set forth changes in our total gross unrecognized tax benefit liabilities, excluding accrued interest, for the years ended December 31, 2025 and 2024:

 SCHEDULE OF UNRECOGNIZED TAX BENEFIT LIABILITIES

     
Balance as of January 1, 2024  $131 
Tax positions - additions   13 
Tax positions - reductions   (47)
Balance as of December 31, 2024   97 
Tax positions - additions   12 
Tax positions - reductions   1 
Balance as of December 31, 2025  $110 

 

Our policy is to accrue interest related to potential underpayment of income taxes with a corresponding increase in income tax expense. The liability for accrued interest as of December 31, 2025 and 2024 was not significant. Interest is computed on the difference between our uncertain tax benefit positions and the amount deducted or expected to be deducted in our filed tax returns.

 

We are subject to income taxes in the U.S. federal jurisdiction and various state jurisdictions. With few exceptions, we are no longer subject to federal and state and local income tax examinations for years before 2021.

 

Historical Timeline

Fiscal YearFiled
2025Mar 26, 2026Showing above
2024Mar 31, 2025
2023Mar 20, 2024
2022Mar 17, 2023
2021Mar 17, 2022
2020Mar 23, 2021
2019Mar 19, 2020
2018Apr 1, 2019
2017Mar 27, 2018
2016Mar 8, 2017
2015Mar 22, 2016

About Income Taxes Disclosures

The income tax disclosure reveals how much a company actually pays in taxes versus what the statutory rate would predict. Analysts focus on the effective tax rate (ETR) reconciliation, which breaks down every item driving the gap between the 21% federal rate and the company's reported ETR — including R&D credits, foreign rate differentials, and state taxes. Deferred tax assets (DTAs) and their valuation allowances signal management's confidence in future profitability: a rising allowance suggests the company doubts it can use accumulated tax benefits. Uncertain tax benefit (UTB) reserves quantify exposure to IRS challenges on aggressive positions.

Key signals to watch: sudden ETR drops without clear operational reasons, large increases in valuation allowances, growing UTB balances, and significant unremitted foreign earnings. Post-TCJA, pay attention to GILTI and BEAT provisions that affect multinational tax structures. Compare the cash taxes paid (from the cash flow statement) against the income tax provision to gauge earnings quality.